LLY vs TSLA: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and Tesla, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-01.
Eli Lilly and Company · Healthcare
$934.34
+17.6% upside to fair value
Grade B
High Quality
VS
Tesla, Inc. · Consumer Cyclical
$387.51
-45.0% upside to fair value
Grade D
QuantHub Verdict
LLY has more upside to fair value
(+17.6%).
LLY trades at a lower forward P/E
(33.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
TSLA |
| Current Price |
$934.34 |
$387.51 |
| Fair Value Estimate |
$1,098.43 |
$213.13 |
| Upside to Fair Value |
+17.6%
|
-45.0%
|
| Market Cap |
$882.8B |
$1,454.1B |
| Forward P/E |
33.1x
|
330.0x
|
| EV / EBITDA |
27.9x
|
122.9x
|
| Price / Sales |
12.2x
|
15.3x
|
| Price / FCF |
65.0x
|
233.8x
|
| Revenue Growth YoY |
+55.5%
|
-3.1%
|
| Gross Margin |
82.7%
|
18.0%
|
| Operating Margin |
46.3%
|
4.6%
|
| Return on Equity |
101.3%
|
4.8%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
1.54%
|
0.43%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Eli Lilly and Company is a leading global pharmaceutical firm with a dominant position in the diabetes and obesity markets, driven by its blockbuster GLP-1 drugs Mounjaro and Zepbound which generated $36.5 billion in FY2025. The company reported $65.2 billion in total revenue for 2025, making it the top pharma by revenue globally. It exhibits high business quality with a durable competitive moat …
Tesla, Inc. is a leading global manufacturer of electric vehicles, energy storage, and solar products, led by CEO Elon Musk since 2008. The company has a mixed business quality profile with a strong brand and innovation leadership but faces significant challenges including declining automotive revenue, which fell nearly 10% year-over-year in 2025, and a 3.1% revenue decline in the most recent qua…
Accumulation Zones
| Metric |
LLY |
TSLA |
| Zone Low |
$823.82 |
$159.85 |
| Zone High |
$933.67 |
$181.16 |
| In Buy Zone? |
No
|
No
|